Related Experiment Video
Updated: Sep 26, 2026

Radiation Planning Assistant - A Web-based Tool to Support High-quality Radiotherapy in Clinics with Limited Resources
Published on: October 6, 2023
Role of General Practitioners in European Health Technology Assessment, EU-HTA Innovation in Oncology as an Example
Daniel Widmer1, Hermenegildo Marcos Carrera1, Jörg Ruof2,3
1European Union of General Practitioners (UEMO), 1000 Brussels, Belgium.
Introduction:
Different from established clinical guideline workstreams, the participation of general practitioners (GPs) in the health technology assessment (HTA) process at the European level is new. There is a research gap in this domain. The European Union of General Practitioners (UEMO) is the political association of GPs in Europe and has been collaborating as a stakeholder in the creation of the European Regulation on HTA since 2017. The aim of our research is to provide a framework for GPs'role in EU HTA.
Methods:
Mixed methods: questionnaire and focus groups.
Participants:
Representatives of national medical/GP associations of 17 Member States of the EU and five EU non-member countries.
Results:
Most respondents supported GP involvement in the development of clinical recommendations relevant to general practice. Respondents emphasized that UEMO must turn to WONCA-Europe, the academic society of GPs, when scientific input is required. Among the ten priority topics for HTA in oncology, four emerged as most relevant for the GPs: 1. Conscientious prescription of interventions considering over- and under-medicalization, 2. establishing a system for continuity of care integrating palliative care, 3. ensuring evidence-based medicine, and 4. promoting collaborative care and considering workload.
Discussion And Conclusions:
The GP can contribute to the debate by defending these four priorities. Presenting the difficulties in this debate can contribute to a better understanding of the implementation of new technology in the real world.
Related Concept Videos
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Therapeutic Drug Monitoring: Affecting Factors
Issues And Trends In Healthcare Delivery System
Cost Containment
Payment for healthcare services has historically promoted adoption of costly and often unnecessary or inefficient...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...